Abbreos, Inc. is an IND-stage company focused on developing a non-invasive and biodegradable oral patch that can treat medical conditions associated with production of potentially lethal amounts of pro-inflammatory cytokines and chemokines (“cytokine storm”). The patch combines a proprietary muco-adhesive surface with an embedded biologic that can calm a hyperactive immune system. The oral patch can be used against cytokine storms associated with a variety of medical conditions in which an infectious agent
plays a role.
We are developing a treatment modality that uses the oral immune system to deliver a biologic (IgG) to calm an overactive immune system. High dose Intravenous immunoglobulin (IVIG) has a long history of successful clinical use to treat autoimmune, infectious and idiopathic diseases. Our OroMucosal ImmunoGlobulin (OMIG) patch uses up to 1000X less immunoglobulin allowing more patients to be served with a lower overall administered dose. The OMIGPatch™ is non-invasive and provides a less costly and more efficient way of administering IgG.